# Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

Study · id `cardio:ct-nct03331289` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03331289](<https://clinicaltrials.gov/study/NCT03331289>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03331289

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.

## Technical summary

Registry record NCT03331289. Randomized; no masking; primary purpose basic science. Start 2018-02-28 (actual); primary completion 2022-03-31 (actual). Results posted on 2023-07-24.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose basic science
- Phase: Phase 4
- Enrolled: 107 participants (enrolled count; ClinicalTrials.gov record NCT03331289, source copy `cardio:ctgov-nct03331289-2023-07-24`, retrieved 2026-10-26)
- Started: 2018-02-28 (actual) (ClinicalTrials.gov record NCT03331289, source copy `cardio:ctgov-nct03331289-2023-07-24`, retrieved 2026-10-26)
- Primary completion: 2022-03-31 (actual) (ClinicalTrials.gov record NCT03331289, source copy `cardio:ctgov-nct03331289-2023-07-24`, retrieved 2026-10-26)
- Completion: 2022-11-04 (actual) (ClinicalTrials.gov record NCT03331289, source copy `cardio:ctgov-nct03331289-2023-07-24`, retrieved 2026-10-26)
- Results first posted: 2023-07-24 (ClinicalTrials.gov record NCT03331289, source copy `cardio:ctgov-nct03331289-2023-07-24`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03331289, source copy `cardio:ctgov-nct03331289-2023-07-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03331289-2023-07-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Placebo
- Intervention (Drug): Exenatide
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Exenatide and Dapagliflozin
- Lead sponsor: The University of Texas Health Science Center at San Antonio
- Lead sponsor class: OTHER
- Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: The University of Texas Health Science Center at San Antonio (`cardio:org-the-university-of-texas-health-science-center-at-san-antonio`)
- Registry lists this organization as a collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (`cardio:niddk`)

## Provenance

Content hash: f360bb38376229c35b8e3a131de7cc115fcee69226f59b0d2692a54797d71436
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
